3,3-substituted indoline derivatives
CA 2371629 A1 · Owner: Ligand Pharmaceuticals, Inc. · Inventors: Ullrich, John W.; Jones, Todd K.; Fensome, Andrew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound of formula (I) and pharmaceutical compositions thereof useful as progesterone receptor antagonist wherein: R1 and R2 are H OH, OAc, alkylaryl, alkylheteroaryl, 1-propynyl optionally substituted alkyl, O(alkyl) aryl, heteroaryl; or R1 and R2 are joined to form a ring a double bond to CMe2; , C(cycloalkyl) O, C(cycloether); R3 = H, OH, NH2, CORA or optionally , substituted alkenyl or alkynyl; RA = H optionally substituted alkyl, alkoxy, aminoalkyl; R4 = H halo, CN, NH2, optionally substituted alkyl alkoxy, or , aminoalkyl; R5 = optionally substituted phenyl a 5- or 6-membered , heterocycle; a 4- or 7-substituted indole or a substituted benzothiophene.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 1, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 1, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 1, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.